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Despite advances in the management of multiple myeloma in the past few decades, it remains an incurable disease. Conventional treatments 
achieve a median survival of 3 to 5 years.1,2 The disease 
follows a relapsing course in the majority of patients, 
regardless of treatment regimen or initial response to 
treatment. Recently, the management of patients with 
multiple myeloma has been transformed by the introl
duction of three novel agents: thalidomide, lenalidol
mide and bortezomib. These three agents represent a 
new generation of therapies for multiple myeloma that 
affect both specific intracellular signaling pathways 
within the tumor cell and also target the tumor microl
environment. This article describes the pivotal trials 
that have led to the incorporation of these novel agents 
in the frontline setting.
Traditionally, newly diagnosed myeloma patients 
have been classified as either transplant or nonltransl
plant candidates. This classification has been based on 
a number of factors including age, performance status, 
colmorbid medical conditions, and patient preference. 
Induction therapy regimens are often decided by a 
patient’s potential transplant status. Transplant candil
dates were typically treated with nonlalkylating agents 
to prevent marrow damage. Nonltransplant candidates 
often received alkylatinglagent based therapy. 
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significant advances in our understanding of the biology of multiple myeloma have led to exciting new 
opportunities in treatment. the management of this disease is rapidly changing with a plethora of clinical 
trials initiated with novel agents, namely thalidomide, lenalidomide and bortezomib, either alone or in 
conjunction with established modalities such as conventional cytotoxic agents and stem-cell transplan-
tation. the combination of these novel agents together with conventional regimens have led to higher 
response rates and survival, providing options for patients whose disease is otherwise resistant to con-
ventional therapy. these pivotal trials that lead to the approval of these three novel agents in treatment 
naïve patients. the potential implications in the frontline treatment paradigm of multiple myeloma are 
discussed.
For those patients preselected for autologous stem 
cell transplantation (ASCT), the degree of clinical rel
sponse was never as important as whether or not they 
actually proceeded to transplant. However, the achievel
ment of complete response (CR) after induction theral
py is now believed to be a strong predictor of longlterm 
survival.3 Unfortunately, traditional induction regimens 
only achieved a limited number of CR or near complete 
(nCR) treatment responses in the range of 3% to 7%.4l
8 In the interim analysis of the currently active multil
center Intergroupe Francophone du Myelome (IFM) 
2005l01 study conducted in Europe, Harousseau et 
al reported a modest CR/nCR rate at 9% only in the 
control arm of vincristine, doxorubicin and dexamethal
sone (VAD).8 There is clearly a need for improvement 
in induction therapy response. Emerging studies have 
shown that the incorporation of novel agents into tradil
tional induction regimens can improve CR/nCR rates 
(Table 1).  
Thalidomide
Thalidomide has been widely used in patients with rel
lapsed or refractory multiple myeloma for a number of 
years. Following the initial report of singlelagent activl
ity in 1999,9 thalidomide has since become one of the 
most widely used drugs to treat multiple myeloma in 
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the relapsed/refractory setting. The FDA has approved 
its use in combination with highldose dexamethasone 
as treatment of newly diagnosed multiple myeloma.
Thalidomide combinations in the frontline setting
The approval of thalidomide plus dexamethasone in the 
frontline setting was based on the results of Eastern 
Cooperative Oncology Group (ECOG) trial E1A00.4 
This was a randomized, controlled phase III trial coml
paring thalidomide 200 mg daily PO plus highldose 
dexamethasone at 40 mg daily on days 1l4, 9l12, 17l
20 (Thal/Dex) repeated monthly for 4 cycles. The 
control arm received high doseldexamethasone alone. 
In total, 207 patients were recruited into the trial. It is 
noteworthy that no specific thromboprophylaxis was 
mandated in this study.The response rate with thalidol
mide plus dexamethasone was significantly higher than 
with dexamethasone alone (63% v 41%, respectively; 
P=.0017). Complete responses occurred in 4% of pal
tients within four cycles of therapy with Thal/Dex, 
and in 0% of patients in the dexamethasonelalone 
arm. Disease progression within four cycles of therapy 
was noted in 2% of patients with Thal/Dex and 5% 
of patients with dexamethasone alone. However, this 
regimen was associated with a significant incidence of 
deep venous thrombosis (DVT), requiring the use of 
anticoagulants like warfarin or low molecular weight 
heparin (LMWH). The incidence rates of grade 3 or 
higher DVT, rash, bradycardia, neuropathy, and any 
grade 4 to 5 toxicity in the first 4 months were signifil
cantly higher with thalidomide plus dexamethasone 
compared with dexamethasone alone (45% vs. 21%, 
respectively; P<.001). This study was also not powered 
to look at overall survival.
Based on a design similar to the ECOG E1A00, 
an extended study  was performed by Rajkumar et al. 
Known as MM 003,10 this phase III trial followed a 
similar design of 4 cycles of ThallDex vs. dexamethal
sone alone. Patients were then subsequently placed on 
maintenance dexamethasone 40 mg on days 1l4 every 
28 days until progression. More than 400 patients 
have been recruited with specific endlpoints looking at 
timeltolprogression (TTP), overall survival (OS), relal
tive response (RR) and most importantly safety issues. 
Using intentionltoltreat analysis, the medianlTTP for 
Thal/Dex was 22.4 months compared with 6.5 months 
for dexamethasone alone (P<.0001). Median OS of 
the dexamethasonelalone arm was 32 months and the 
OS for the Thal/Dex group had not been reached yet 
as of the time of writing. Increased toxicities in the 
combination Thal/Dex arm in particular in the form 
of thrombotic events were reconfirmed (Table 2).
Thalidomide plus dexamethasone versus VAD as ind
duction treatment
A randomized trial compared Thal/Dex with vincrisl
tine/doxorubicin/dexamethasone (VAD) as an inducl
tion regimen prior to ASCT in newly diagnosed mull
tiple myeloma patients up to 65 years of age.11 Since 
2003, 204 patients were randomly assigned to receive a 
4lmonth treatment with Thal/Dex (n=100) or a VADl
like regimen (n=104). All patients were intended to 
proceed to peripheral blood stem cell (PBSC) mobilil
zation and to receive highldose therapy with melphalan 
200 mg/m2 (MELl200) and autologous PBSC support. 
The main characteristics of patients in each arm were 
similar. In both arms, 91% of patients proceeded to 
PBSC mobilization, PBSC harvests were similarly sucl
cessful, and 83% of patients received highldose therapy 
and ASCT. Very good partial response (VGPR, defined 
by serum and urine Mlprotein detectable by immunol
fixation but not on electrophoresis or 90% or greater 
reduction in serum Mlprotein plus urine Mlprotein 
level <100mg per 24 h) rates were significantly higher 
in the Thal/Dex arm before PBSC collection (25% vs. 
6%, P=.0027) and before highldose therapy and ASCT 
Table 1. Summary of response rates using traditional induction regimens for patients with newly diagnosed multiple myeloma.






Rajkumar et al 20064 100 Dexamethasone 0% 50% yes
Rifkin et al. 20066 97 DVd 3% 43% yes
iFm90 19967 100 VmCp 5% 52% yes/No
palumbo et al 20065 126 mp 7% 48% No
Harousseau et al 20068 82 VaD 9% 67% yes
CR: complete response, nCR: near complete response, pR: partial response. VaD: vincristine, doxorubicin, dexamethasone; DVd: liposomal doxorubicin, vincristine, 
dexamethasone; VmCp: vincristine, melphalan, cyclophosphamide, prednisolone, carmustine, and doxorubicin, mp: melphalan, prednisolone
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Table 2. Summary of results and adverse events of phase iii trials comparing thalidomide vs. thalidomide plus dexamethasone. 
   
 
MM-0031010 E1A0044
Thal/Dex (n=234) Dex (n=232) Thal/Dex (n=103) Dex (n=104)
Time-to-progression (months) 22.4 6.5 Not determined Not determined
Overall survival  (months) Not Reached 32 Not determined Not determined
Adverse Events Grade ≥3 
Deep vein thrombosis 18% 3% 17% 3%
pneumonia 11% 7% NR NR
Bradycardia 2% 0% 1% 0%
peripheral Neuropathy NR NR 7% 4%
any toxicities, grade ≥4 30% 23% 34% 18%
(35% vs. 12.5%, P=.002), but the benefit was not seen 6 
months after transplant. Venous thromboembolism or 
pulmonary embolism was higher in the Thal/Dex arm 
versus the VAD arm (22.8% vs. 7.5%, P=.004). Toxicity 
profiles were otherwise similar. Before PBSC mobilizal
tion, the mean duration of hospitalization regardless of 
cause was significantly lower in the Thal/Dex arm (8.3 
days vs. 20 days, P=.0001). This study confirms that 
Thal/Dex is an effective firstlline treatment for multiple 
myeloma and supports its use as an induction regimen, 
which could be preferred to infusions of VAD in candil
dates for highldose therapy.
Thalidomide and melphalan and prednisolone (MPT) 
in the elderly population
Although autologous stemlcell transplantation (autol
SCT) has been associated with longer progressionlfree 
survival, many patients diagnosed with myeloma are 
elderly with colmorbid conditions which may render 
them unfit for autolSCT. For these patients, the stanl
dard treatment has been combination melphalan/predl
nisolone (MP) without stem cell transplantation. 
Palumbo et al5 looked at the addition of thalidomide 
to melphalan and prednisolone (MPT) in a phase III 
trial involving an elderly patient population older than 
65 years of age. The rate of complete responders qual
drupled from 7% with MP to 28% with MPT with an 
increase in the overall response rate from 48% to 76%. 
Median progressionlfree survival also increased from 
14 months to 33 months and 2lyear event free survival 
improved from 27% to 54% in favor of the tripleldrug 
arm (Hazard ratio for MPT 0.51, 95% CI 0.35l0.75, 
P=.0006). There was also a trend towards improved 
overall survival rate at 3 years of 64% in the MP alone 
compared to 80% for the MPT arm.
In the threelarm phase III IFM 99l06 trial, Facon et 
al12 compared MPT to MP and melphalanlbased autol
SCT (MELl100) in patients aged 65l75 years with 
newly diagnosed multiple myeloma. Initially planned 
for a recruitment of more than 480 patients, during the 
third interim analysis in 2005, results showed a clear sul
periority for the MPT arm and further enrollment was 
stopped. The PFS time was significantly longer in the 
MPT group than in the MP arm (RR=2.4, P<.0001), 
but no significant difference was noted between the 
MP and MEL100 groups (Relative risk=1.2, P=0.12). 
There was a clear advantage in favor of MPT vs. MEL 
100 (Relative risk=2.0, P=.0001). The PFS advantage 
in favor of MPT translated to a significant benefit in 
terms of OS. The median OS time was 30.3 months 
and 38.6 months for MP and MELl100 groups, respecl
tively, while the median OS had not been reached yet at 
56 months. Thus it was concluded that MPT should 
be, at the present time, the reference treatment for newl
ly diagnosed multiple myeloma patients ineligible for 
autologous stem cell therapy (Table 3).
Thalidomide, thromboembolism and thromboprophyd
laxis
Although venous thromboembolism is a common coml
plication in cancer patients, therapy with thalidomide 
combinations appears to substantially increase this 
risk.4,13 Prophylaxis with therapeutic doses of warfarin 
or lowlmolecular weight heparin (LMWH) has been 
advised,13,14 while aspirin may also reduce the risk of 
venous thromboembolic events. However, it has been 
suggested that this should only be reserved for patients 
unable or unwilling to take warfarin or LMWH. As 
these studies were performed in the West, whether the 
thromboembolic risk is equally as high in our predomil
nantly nonlCaucasian population has yet to be valil
dated.
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Table 3. Results of iFm 99-06 at the 3rd interim analysis in 2005.12 











mpT 29.5±3.6 > 56
mel100 19.0±1.3 38.6±3.0
mp: melphalan and prednisolone; mpT: melphalan and prednisolone plus thalidomide, mel100: (VaD×2 cycles, cyclophosphamide 3g/m2+stem cell harvest, and 2 courses of 
melphalan 100 mg/m2+stem cell reinfusion.
Other side effects of thalidomide
Aside from the potential of thromboembolism menl
tioned previously, the most common adverse events 
associated with thalidomide treatment are constipal
tion, fatigue, somnolence and peripheral neuropathy.9,15 
Peripheral neuropathy is a common adverse event that 
often limits the dose and duration of treatment. In a retl
rospective analysis of a phase II Mayo Clinic trial,16 56% 
of patients were identified as having developed sympl
toms of peripheral neuropathy. Neuropathy improved 
in 27% during the treatment phase with/without dose 
reduction or after cessation of thalidomide. Fifteen 
percent of patients worsened despite dose reduction or 
stopping thalidomide while 52% remained stable durl
ing treatment. Most patients experienced grade 1 neul
ropathy only, but 11% of all patients had grade 2 neul
ropathy and 2% had grade 3 neuropathy. Predominant 
symptoms of neuropathy were tingling and numbness 
involving both the upper limb and lower limbs. Small 
subsets of patients complained of hearing loss and erecl
tile dysfunction. In view of the toxicity profile of thal
lidomide, its analogue lenalidomide was developed with 
the aim of retaining its clinical efficacy but improving 
the toxicity profile.
Lenalidomide (Revlimid)
Lenalidomide belongs to a class of drugs known as 
IMiDs (immunomodulatory drugs) that are structurl
ally related to thalidomide, but have relatively increased 
potency and differing side effect profiles. Results from 
phase I and II studies have shown lenalidomide to have 
significant and durable singlelagent activity in the rel
lapsed setting with responses seen in 14% to 29% of 
patients.17,18 
When combined with dexamethasone in a phase III 
randomized study involving more than 140 relapsed 
or refractory multiple myeloma patients, Weber et al19 
demonstrated greater efficacy in the lenalidomide plus 
dexamethasone group compared with dexamethasone 
alone, achieving a response rate of 59% vs. 21% (P<.001) 
and a CR rate of 13% vs. <1% (P<.001). With these enl
couraging results, lenalidomide has been investigated in 
the upfront setting.
Lenalidomide combinations in the frontline setting
Phase II studies have investigated the use of lenalidol
mide combinations in newly diagnosed multiple myl
eloma. In 34 newly diagnosed multiple myeloma pal
tients, Macy et al20 demonstrated an astonishing overall 
response rate of 90% at 4 months with 48% of patients 
achieving CR or VGPR. Ninety percent of patients rel
mained alive after 2 years and the 2lyear PFS was 59%. 
Aspirin was an effective DVT prophylaxis.
Under the auspices of ECOG, Rajkumar et al furl
ther investigated first line use of lenalidomide and 
dexamethasone in a phase III setting.21 ECOG E4A03 
compared high dose dexamethasone (i.e. standard dose 
at 480 mg/cycle) vs. low dose dexamethasone (i.e. 160 
mg/cycle) in combination with lenalidomide. More than 
400 patients had been recruited at the time of writing. 
At the second prelplanned interim analysis presented at 
the American Society of Hematology (ASH) Meeting 
in 2007, OS was significantly superior with the lenalidl
omide plus low dose dexamethasone arm compared to 
the lenalidomide plus high dose dexamethasone arm, 
with a 1lyear survival at 96% vs. 87% (P<.001), respecl
tively. The 18lmonth survival rate was 91% versus 80%, 
respectively. 
Although there was a significantly greater incidence 
of DVT/pulmonary embolism in the highldose arm 
(18.4% vs. 6.3%, P<.001), further analysis of the data 
showed that the poorer overall survival of the highl
dose dexamethasone arm could not be explained by 
this adverse event alone. The increased mortality in the 
highldose dexamethasone group was due to disease 
progression (myeloma deaths) as well as increased toxl
icity. Thus, the study has major implications for the use 
of highldose dexamethasone in the treatment of newly 
diagnosed multiple myeloma (Table 4).
Clinical trials are currently being performed assessl
ing lenalidomide in combination with other agents. 
Lenalidomide and melphalan/prednisolone has been 
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Table 4. Results of eCOG e4a03-phase iii Trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose 
dexamethasone in newly diagnosed multiple myeloma.21











D1, D8, D15, D22
Total: 160 mg/cycle
DVT /pulmonary embolism 18.4 6.3 <.001
infection/pneumonia 16.1 9.0 .031
Fatigue 11.7 4.1 .004
Hyperglycemia 5.8 2.3 .090
Neuropathy 0.4 1.4 .372
any non-hematologic 54.3 39.6 .002
any toxicity (≥ grade 4) 19.3 11.3 .025
Death (grade 5) 4.9 0.5 .006
investigated in elderly patients with newly diagnosed 
multiple myeloma.22 Preliminary results show that the 
combination produces at least a partial response in 81% 
of patients with 47.6% of patients achieving VGPR and 
24% achieving CR. Hematologic adverse events were 
frequent but noted as manageable. Nonlhematologic 
adverse events were low. Aspirin appeared to provide 
adequate antilthrombosis prophylaxis.
Side effects of lenalidomide
Studies show that lenalidomide is better tolerated 
than thalidomide in several aspects of its toxicity prol
file. Clinically significant somnolence, constipation 
and neuropathy rarely occurred in prior studies. 
Myelosuppression, mainly in the form of neutropenia 
and thrombocytopenia are the most common grade ≥ 3 
toxicities,18 but are manageable with dose reduction and 
growth factor support. As seen in thalidomide, the risk 
of thromboembolic events is also higher in combination 
with dexamethasone and antilthrombotic prophylaxis 
is advised.
Bortezomib (Velcade)
Bortezomib is a novel, firstlinlclass proteasome inhibil
tor that has antilproliferative, prolapoptotic, antilanl
giogenic and antiltumor activity through the inhibition 
of proteasomal degradation of numerous regulatory 
proteins.23,24 Prelclinical studies have demonstrated 
synergistic or additive antiltumor activity with agents 
commonly used in the treatment of multiple myeloma.
Bortezomib with or without dexamethasone was 
shown to be active in two phase II studies in patients 
with relapsed/refractory myeloma.25,26 The internationl
al, randomized phase III Assessment of Proteasome 
Inhibition for Extending Remissions (APEX) trial rel
cruited patients with relapsed multiple myeloma followl
ing 1 to 3 prior therapies.27 It showed that singlelagent 
bortezomib provides a significantly longer TTP, higher 
response rate and superior survival compared with highl
dose dexamethasone. The combined complete and parl
tial response rates were 38% for bortezomib and 18% 
for dexamethasone (P<.001), and the CR rates were 
6% and <1%, respectively (P<.001). Median TTP in 
the bortezomib and dexamethasone groups were 6.22 
months (189 days) and 3.49 months (106 days), respecl
tively (hazard ratio, 0.55; P<.001). Substantial activity 
has also been demonstrated in bortezomiblbased coml
binations in the relapsed/refractory setting.
Bortezomib combinations in the frontline setting
Bortezomiblbased therapies have demonstrated enl
couraging activity in at least 13 studies in the frontline 
setting,28 both as induction therapy prior to stem cell 
transplantation and as therapy for patients not proceedl
ing to, or not eligible for transplant. In total, more than 
700 patients involved in these trials have shown high 
response rates and consistently higher CR/nCR rates 
than that seen in conventional induction regimens and 
conventional therapies.
The double regimen of bortezomib plus dexal
methasone has been investigated as induction therapy 
in at least 3 trials.29l31 In a singlelarm phase II study, 
Jagannath et al29 investigated the use of bortezomib, as 
a single agent and in combination with dexamethasone 
in the firstlline setting. Thirtyltwo consecutive patients 
received bortezomib for a maximum of six 3lweek cyl
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cles with oral dexamethasone 40 mg added if a less than 
a partial response was achieved after two cycles or a less 
than CR was achieved after four cycles. The response 
rate (CR+PR) was 88%, with undetectable paraprol
tein (CR) in 6% and paraprotein detected by immunol
fixation only (nCR) in 19%. All 32 patients completed 
the first two cycles of bortezomib alone, of whom 3% 
achieved CR, 9% nCR, and 28% PR. Most patients 
responded within 4 cycles with the medianltimeltolrel
sponse of 1.9 months. It is noteworthy that bortezomib 
treatment did not affect stem cell mobilization in eight 
or transplantation in six patients (Table 5). 
 The IFM 2005l01 is a large randomized phase III 
trial comparing bortezomib/dexamethasone vs. VAD as 
induction therapy prior to autologous stemlcell transl
plantation. Involving more than 480 patients, it coml
pleted accrual in January 2007. Interim analysis of the 
first 220 patients recruited was presented at the ASH 
Annual Meeting in 2007 in abstract form.32 Although 
the difference in achieving “more than partial response” 
was insignificant between the VAD and the bortezol
mib/dexamethasone arm both at postlinduction and 
postlASCT, significantly more patients in the bortezol
mib/dexamethasone arm established CR+nCR and 
VGPR (9% vs. 22%; P=.0085; 24% vs. 50%; P=.001 
respectively) at postlinduction. We eagerly await furl
ther results from this trial.
Table 5. Results from bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple 
myeloma.29 





Overall response 49 78 88
partial response 37 57 49
Very good partial response 2 6 20
Complete response, near 
complete response 10 14 18
Regimens containing bortezomib and doxorubicin 
have also demonstrated substantial activity. In a phase 
II study, the combination of bortezomib, doxorubicin 
and dexamethasone (PAD)33 yielded a response rate 
of 95%, including a 29% CR/nCR rate, prior to steml
cell transplantation (SCT). This high response rate 
was sustained even after SCT and is important as CR 
status following SCT is associated with longer overall 
survival time.34,35 The efficacy of bortezomib and pel
gylated liposomal doxorubicin (PLD; Doxil) has been 
validated in a randomized phase III international trial 
in the refractory or relapsed setting.36 Median timel
tolprogression was increased from 6.5 months for 
bortezomib to 9.3 months with the PLD+bortezomib 
combination (P=.000004; hazard ratio, 1.82 [monol
therapy v combination therapy]; 95% CI, 1.41 to 2.35) 
but as yet, no survival advantage has been demonstratl
ed to date.
In June 2008, based on the pivotal phase III VISTA 
trial37 involving 682 patients, bortezomib was approved 
by the FDA in combination with melphalan and predl
nisolone in the frontline setting for patients who are 
ineligible for SCT. This phase III multilcenter open lal
bel study randomized patients to receive bortezomib in 
addition to melphalan and prednisolone (VMP) verl
sus a control group of the dual combination of melphal
lan and prednisolone (MP). Interim analysis showed 
Table 6. Recommended dose modifications of bortezomib in the event of peripheral neuropathy.38
Severity of peripheral neuropathy Modification of dose and schedule
Grade 1 (paresthesias or loss of reflexes) without pain or loss 
of function No action
Grade 1 with pain or grade 2 (interferes with function but not 
with aDl) Reduce to 1.0 mg/m
2
Grade 2 with pain or grade 3 (interferes with aDl) Withhold treatment until toxicity resolves, then reinitiate at a dose of 0.7 mg/m2 once weekly
Grade 4 (permanent sensory loss that interferes with function) Discontinue treatment
abbreviation: aDl, activities of daily living.
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a CR rate of 35% with the tripleldrug combination, 
compared with 5% with the control arm (P<.000001). 
Median duration of response was 24 months for pal
tients with a CR after VMP, compared with 13 months 
after MP; the timeltoldisease progression was 24 
months and 17 months (P=.0000001), respectively. In 
addition, the tripleldrug combination demonstrated a 
statistically significant improvement in OS, with a 40% 
reduction in the risk for death (P=.0078). 
Side effects of bortezomib
Most common toxicities associated with bortezomib 
treatment include fatigue, gastrointestinal events and 
peripheral neuropathy. The most commonly reported 
grade ≥3 toxicities are peripheral neuropathy and myl
elosuppression with anemia, thrombocytopenia and 
neutropenia. Bortezomiblrelated peripheral neuropal
thy is an important dosellimiting toxicity,38 but was 
shown to be reversible in the majority of patients. Based 
on the earlier two phase II trials of bortezomib in the 
refractory setting,25,26 a dose modification guideline in 
the event of neuropathy has been developed (Table 6).
Conclusions
Prior to the advent of these novel agents, extensive work 
performed by the French IFM group and Barlogie et al39 
advocated tandem stemlcell transplants as the standard 
of care to achieve a higher CR rate, especially in the 
younger population. However, with the availability of 
novel agents, the treatment paradigm of multiple myl
eloma has changed dramatically. With the introduction 
of these therapies in the firstlline treatment setting, the 
number of objective responses has increased dramatil
cally and consistently, as has the number of complete 
responses. The results indicate that combining a novel 
agent with standard chemotherapy increases the numl
ber of complete and near complete responders to 20% or 
30%, a number that was previously unheard of outside 
of a transplant. Notably, this is usually achieved withl
out compromising the dose of either the novel agent 
or standard chemotherapy. In view of these encouragl
ing results, the role of autologous stemlcell transplant, 
especially in the older population, is now being called 
into question. The ultimate impact of novel agents may 
be to extend survival in younger patients by achieving 
CR prior to a single autologous transplant as consolil
dation treatment. The survival of older patients may 
improve following induction therapy with novel agents 
without the need for autologous transplant. Further 
stratification of patients into distinct risk groups based 
on molecular cytogenetics may also play an important 
role in deciding treatment options.40
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